iShares Neuroscience and Healthcare ETF (IBRN) Dividend Yield, History & Forecast

iShares Neuroscience and Healthcare ETF (IBRN) is an exchange-traded fund (ETF) listed on the New York Stock Exchange Arca. It pays a current dividend yield of 0.96% ($0.32 per share annually (TTM)). The most recent ex-dividend date was December 16, 2025, with payment scheduled for December 19, 2025. market capitalization is approximately $5M. Review IBRN dividend history on this scorecard, compare peers in the Compare Dividend Returns tool, or project income with the dividend calculator.

IBRN fund composition

IBRN holds 68 positions, with 45.0% of assets in its ten largest. It charges an expense ratio of 0.47%, and manages $6.7M.

Top 10 holdings

HoldingWeight
PRAXPRAXIS PRECISION MEDICINES5.24%
DNTHDIANTHUS THERAPEUTICS INC4.99%
ACADACADIA PHARMACEUTICALS4.91%
SRRKSCHOLAR ROCK HOLDING4.76%
XENEXENON PHARMACEUTICALS4.37%
ARGXARGENX SE ADR4.35%
ARWRARROWHEAD PHARMACEUTICALS4.27%
BIIBBIOGEN4.17%
ALKSALKERMES4.16%
PTCTPTC THERAPEUTICS3.75%

Sector allocation

Healthcare100.0%Cash & Others0.4%

Frequently Asked Questions about iShares Neuroscience and Healthcare ETF (IBRN)

What is iShares Neuroscience and Healthcare ETF's dividend yield?
iShares Neuroscience and Healthcare ETF (IBRN) pays a current trailing twelve-month dividend yield of 0.96%, which works out to $0.32 per share annually based on the most recent payout schedule.
When does iShares Neuroscience and Healthcare ETF pay distributions?
The most recent ex-dividend date was December 16, 2025. The next scheduled dividend payment date is December 19, 2025.
How many years has iShares Neuroscience and Healthcare ETF increased its dividend?
iShares Neuroscience and Healthcare ETF (IBRN) has increased its dividend for 1 consecutive year.
What does iShares Neuroscience and Healthcare ETF invest in?
The iShares Neuroscience and Healthcare ETF (IBRN) aims to mirror the financial performance of a particular index. This index consists of companies, both domestically in the U.S. and from other countries, that are expected to benefit from new discoveries and the overall growth in the field of neuroscience.